Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Biosimilar Labeling Variation From Reference Product OK, FDA Says

Executive Summary

A biosimilar that is not licensed for all of the indications on a reference product's label may still need to include some information about that off-label indication to ensure safe use, draft guidance says.


Related Content

Biosimilar Labeling: US FDA’s Final Guidance Means Status Quo For Sponsors
Biosimilar Labeling Carve-Out Turned Erelzi's Psoriatic Arthritis, Plaque Psoriasis Uses Into 'Another Indication'
Biosimilar Sponsors Took Delivery Device Shortcuts For Erelzi, Amjevita
Sandoz’s Erelzi: Biosimilar Pediatric Labeling Strayed From Enbrel
Biosimilar Labeling: Should FDA Just Throw Up Its Hands And Finalize Guidance?
How To Label A Biosimilar? Copy The Reference Product, FDA Told Sandoz


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts